(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 114.12% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.41%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.75%.
Autolus Therapeutics's revenue in 2025 is $29,934,000.On average, 3 Wall Street analysts forecast AUTL's revenue for 2025 to be $22,337,514,767, with the lowest AUTL revenue forecast at $19,003,827,452, and the highest AUTL revenue forecast at $25,850,315,250. On average, 3 Wall Street analysts forecast AUTL's revenue for 2026 to be $50,816,242,592, with the lowest AUTL revenue forecast at $34,731,986,418, and the highest AUTL revenue forecast at $78,099,197,058.
In 2027, AUTL is forecast to generate $77,988,748,372 in revenue, with the lowest revenue forecast at $56,609,874,968 and the highest revenue forecast at $118,294,534,361.